Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
2 "lipid profile"
Article category
Publication year
Original Articles
The long term effects of rosiglitazone on serum lipid concentration and body weight.
Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Yu Mie Rhee, Chul Woo Ahn, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee, Bong Soo Cha
Korean Diabetes J. 2006;30(1):17-24.   Published online January 1, 2006
  • 2,176 View
  • 17 Download
AbstractAbstract PDF
Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentration and low density lipoprotein (LDL) particle size, it has adverse effects on the increment of total cholesterol (TC) and LDL cholesterol (LDL-C), and body weight in some studies. Such adverse effects of rosiglitazone on the serum lipid profiles and body weight seem to be attributed to the fact that most studies with rosiglitazone are limited to a short period of follow up. The aim of this study was to evaluate the long term effects of rosiglitazone on the serum lipid levels and body weight. MATERIALS AND METHODS: We prospectively evaluated fasting serum glucose, HbA1c, TC, LDL-C, triglyceride, HDL-C and body weight at baseline and every three months after rosiglitazone usage (4mg/d) in 202 type 2 diabetic patients. RESULTS: TC levels had increased maximally at 3 months and thereafter decreased, but were significantly higher at 18 months than those at baseline. LDL-C levels from the first 3 months to 12 months were significantly higher than those at baseline, but after 15 months, LDL-C concentration was not significantly different from the basal LDL-C concentration. HDL-C levels had increased after first 3 months and the increment of HDL-C concentration were maintained. The increment of HDL-C was more prominent in patients with low basal HDL-C concentration than in patients with high basal HDL-C concentration. Body weight from 3 months to 18 months were higher than that at baseline, but after 3 months, body weight did not increase furthermore significantly. CONCLUSIONS: The adverse effects on lipid concentration and body weight of rosiglitazone may attenuate after long term usage of rosiglitazone.
The Relationship between Apolipoprotein E Phenotypes, Serum Lipid Metabolism, and Oxidative Stress in Korean Type 2 Diabetic Patients.
Soo Bong Choi, Sun Min Park
Korean Diabetes J. 1999;23(2):182-192.   Published online January 1, 2001
  • 957 View
  • 16 Download
AbstractAbstract PDF
The cause of type 2 diabetes mellitus (DM) is not known, but one of the causes may be the reduction of insulin secretion through the fibrosis formed with amyloid deposits in pancreatic beta cells. Amyloidogenesis in hippocampus is a characteristic feature in Alzheimers disease. Possession of the Apolipoprotein (Apo) E 4 allele (E4/2, FA/3 or E4/4) is a risk factor for the development of Alzheimers disease. However, it is controversial that Apo E polymophsim is associated with the etiopathology of type 2 DM. Both Alzheimers disease and type 2 DM has increased oxidative stress, which may be related to the formation of fibrosis. The purpose of this study was to investigate the distribution of Apo E phenotypes in type 2 diabetic subjects and healthy subjects, and to determine whether Apo E phenotypes influenced serum lipid profiles and glutathione peroxidase and superoxide dismutase activities of red blood cells in type 2 DM and healthy subjects. METHODS: Overnight fasting blood was collected from 84 type 2 diabetic patients and 85 healthy subjects. Apo E phenotypes was determined by the isoelectrofocusing method. Serum lipid profiles and supetoxide dismutase and glutathione peroxidase activ'ities of red blood cells (RBC) were measured. RESULTS: The frequency of Apo E 4 in the type 2 DM was higher than that in the control group (p<0,05). The serum total cholesterol and triglyceride levels of the type 2 DM were overall higher than in healthy subjects. Serum lipid profiles were not affected by Apo E phenotypes in healthy subjects. However, semm total cholesterol levels of type 2 diab diabetic patients with Apo E3/3 were signifcantly lower than those with Apo FA/3 (p<0.05), but serum HDL, cholesterol levels had an opposite tendency. Serum triglyceride levels of type 2 diabetic patients with Apo E3/2 were higher than those with Apo E4/3 (p<0.05), RBC superoxide dismutase and gluta,thione peroxidase activities in type 2 diabetic patients tended to be lower than those in the control group. These enzyme activities of type 2 diabetic patieints with Apo E3 were lowest among the Apo E phenotype groups (p<0.05). CONCLUSION: This result suggests that type 2 diabctic patients had more Apo E 4 allele than in healthy people. Antioxidant enzyme activities decrqased in type 2 diabetic patients with Apo E 4 allele. Serum lipid profiles of type 2 diabetic patients with Apo E 4 allele was an increased risk factor for cardiovascular disease.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer